logo-loader
viewTissue Regenix Group PLC

Tissue Regenix raises cash to expand manufacturing capacity in the US

“Not only do we expect this investment to provide the capacity required to scale our business and drive our commercial success, it will also increase the number of patients who can benefit from our broadened product portfolio" said Gareth Jones, interim chief executive officer

Tissue Regenix Group PLC -

Tissue Regenix PLC (LON:TRX) has raised £14.6mln via a placing of shares at 0.25p each to fund the group's manufacturing capacity expansion programme in the US, which is commencing immediately, and for general working capital purposes.

In total, 5.85bn new shares were issued via the placing and share subscription while a further 800mln shares were taken up by retail and other private investors through the PrimaryBid.com platform at the same price, raising an additional £2mln.

Gareth Jones, the interim chief executive officer of Tissue Regenix, expressed delight at the support shown by both new and existing investors.

“We continue to experience strong demand for our products. This injection of additional capital will allow for the commencement of the planned manufacturing capacity expansion in the US enabling us to increase the output of our San Antonio facility, unlock additional revenues and realise new partnership opportunities we foresee potentially emerging,” Jones said in a statement.

“Not only do we expect this investment to provide the capacity required to scale our business and drive our commercial success, it will also increase the number of patients who can benefit from our broadened product portfolio," he added.

Shares in Tissue Regenix closed at 0.97p last night.

Quick facts: Tissue Regenix Group PLC

Price: 0.35 GBX

AIM:TRX
Market: AIM
Market Cap: £24.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read